scholarly journals Marginally reduced maternal hepatic and splenic ferroportin under severe nutritional iron deficiency in pregnancy maintains systemic iron supply

2021 ◽  
Author(s):  
Rafał Mazgaj ◽  
Paweł Lipiński ◽  
Eunice Sindhuvi Edison ◽  
Aleksandra Bednarz ◽  
Robert Staroń ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Supply ◽  
In Pregnancy

Plexafer-F in the Management of Latent Iron Deficiency in Pregnancy

1978 ◽  
Vol 6 (1) ◽  
pp. 34-40 ◽  
Author(s):  
A M Afifi
Keyword(s):  
Folic Acid ◽  
Iron Deficiency ◽  
Ferrous Sulphate ◽  
Drug Intake ◽  
Iron Supply ◽  
Child Bearing ◽  
High Incidence ◽  
Latent Iron Deficiency ◽  
Stool Specimens ◽  
In Pregnancy

The failure to prescribe in antenatal clinics a well tolerated form of supplementary oral iron that provides an adequate iron supply for the successful maintainance of active erythropoiesis in pregnant women largely accounts for the frequent development of latent iron deficiency in the child-bearing age. The potential value of Plexafer-F*, a slow release ferrous sulphate preparation supplemented with folic acid, in reducing the high incidence of latent iron deficiency in pregnancy was assessed by conducting a randomized clinical trial of Plexafer-F and ordinary ferrous sulphate B.P. with folic acid in eighty women presenting early in pregnancy with latent iron deficiency. At the end of the trial, which was started at the sixteenth week of pregnancy and which lasted for twenty weeks, normal haematological values were obtained in thirty-eight out of forty patients (95%) taking Plexafer-F, but only in twenty-four out of forty patients (60%) taking ferrous sulphate. A simple screening test run on stool specimens provided during antenatal visits to check regular ingestion of the iron preparations prescribed, revealed regular drug intake and no intolerance in all the patients receiving Plexafer-F, against an intolerance leading to failure of regular drug intake in 37.5% of patients receiving ordinary ferrous sulphate.

scholarly journals Maternal Iron Status in Pregnancy and Child Health Outcomes after Birth: A Systematic Review and Meta-Analysis

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2221
Author(s):  
Hugo G. Quezada-Pinedo ◽  
Florian Cassel ◽  
Liesbeth Duijts ◽  
Martina U. Muckenthaler ◽  
Max Gassmann ◽  
...  
Keyword(s):  
Systematic Review ◽  
Iron Deficiency ◽  
Child Health ◽  
Methodological Quality ◽  
Iron Status ◽  
Meta Analysis ◽  
Child Health Outcomes ◽  
Maternal Iron ◽  
In Pregnancy

In pregnancy, iron deficiency and iron overload increase the risk for adverse pregnancy outcomes, but the effects of maternal iron status on long-term child health are poorly understood. The aim of the study was to systematically review and analyze the literature on maternal iron status in pregnancy and long-term outcomes in the offspring after birth. We report a systematic review on maternal iron status during pregnancy in relation to child health outcomes after birth, from database inception until 21 January 2021, with methodological quality rating (Newcastle-Ottawa tool) and random-effect meta-analysis. (PROSPERO, CRD42020162202). The search identified 8139 studies, of which 44 were included, describing 12,7849 mother–child pairs. Heterogeneity amongst the studies was strong. Methodological quality was predominantly moderate to high. Iron status was measured usually late in pregnancy. The majority of studies compared categories based on maternal ferritin, however, definitions of iron deficiency differed across studies. The follow-up period was predominantly limited to infancy. Fifteen studies reported outcomes on child iron status or hemoglobin, 20 on neurodevelopmental outcomes, and the remainder on a variety of other outcomes. In half of the studies, low maternal iron status or iron deficiency was associated with adverse outcomes in children. Meta-analyses showed an association of maternal ferritin with child soluble transferrin receptor concentrations, though child ferritin, transferrin saturation, or hemoglobin values showed no consistent association. Studies on maternal iron status above normal, or iron excess, suggest deleterious effects on infant growth, cognition, and childhood Type 1 diabetes. Maternal iron status in pregnancy was not consistently associated with child iron status after birth. The very heterogeneous set of studies suggests detrimental effects of iron deficiency, and possibly also of overload, on other outcomes including child neurodevelopment. Studies are needed to determine clinically meaningful definitions of iron deficiency and overload in pregnancy.

Iron and folic acid in pregnancy: ferrograd folic

1968 ◽  
Vol 6 (3) ◽  
pp. 12.1-12
Keyword(s):  
Folic Acid ◽  
Iron Deficiency ◽  
Slow Release ◽  
Ferrous Sulphate ◽  
Elemental Iron ◽  
Ferrous Fumarate ◽  
Iron And Folic Acid ◽  
In Pregnancy

Abbott Laboratories have drawn our attention to their Ferrograd Folic tablets which were introduced shortly after we discussed combined iron and folic acid tablets (DTB March 17, 1967, p. 22.). Like A. H. Cox’s ferrous fumarate and folic acid tablet (DTB November 24, 1967, p. 96), Ferrograd Folic provides what we concluded were appropriate amounts of folic acid and iron for prophylaxis of folate and iron deficiency in pregnancy. Each tablet contains 350 mcg folic acid and 105 mg elemental iron as slowly released ferrous sulphate; the dose is one tablet daily. The basic NHS cost of one week’s supply is 1/9d, much more than that of Cox’s tablets, but slow release of the iron is probably an advantage for some patients.

scholarly journals Prevalence and aetiologies of anaemia among first trimester pregnant women in Sri Lanka; the need for revisiting the current control strategies

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Gayani Shashikala Amarasinghe ◽  
Thilini Chanchala Agampodi ◽  
Vasana Mendis ◽  
Krishanthi Malawanage ◽  
Chamila Kappagoda ◽  
...  
Keyword(s):  
Public Health ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Blood Count ◽  
First Trimester ◽  
Full Blood Count ◽  
Red Cell ◽  
Middle Income ◽  
Anaemia In Pregnancy ◽  
In Pregnancy

Abstract Background The Sustainable development goals, which focus strongly on equity, aim to end all forms of malnutrition by 2030. However, a significant cause of intergenerational transfer of malnutrition, anaemia in pregnancy, is still a challenge. It is especially so in the low- and middle-income settings where possible context-specific aetiologies leading to anaemia have been poorly explored. This study explores the prevalence of etiological factors significantly contributing to anaemia in pregnancy in Sri Lanka, a lower-middle-income country with a high prevalence of malnutrition albeit robust public health infrastructure. Methods All first-trimester pregnant women registered in the public maternal care programme in the Anuradhapura district from July to September 2019 were invited to participate in Rajarata Pregnancy Cohort (RaPCo). After a full blood count analysis, high-performance liquid chromatography, peripheral blood film examination, serum B12 and folate levels were performed in anaemic participants, guided by an algorithm based on the red cell indices in the full blood count. In addition, serum ferritin was tested in a random subsample of 213 participants. Anaemic women in this subsample underwent B12 and folate testing. Results Among 3127 participants, 14.4% (95%CI 13.2–15.7, n = 451) were anaemic. Haemoglobin ranged between 7.4 to 19.6 g/dl. 331(10.6%) had mild anaemia. Haemoglobin ≥13 g/dl was observed in 39(12.7%). Microcytic, normochromic-normocytic, hypochromic-normocytic and macrocytic anaemia was observed in 243(54%), 114(25.3%), 80(17.8%) and two (0.4%) of full blood counts in anaemic women, respectively. Microcytic anaemia with a red cell count ≥5 * 106 /μl demonstrated a 100% positive predictive value for minor haemoglobinopathies. Minor hemoglobinopathies were present in at least 23.3%(n = 105) of anaemic pregnant women. Prevalence of iron deficiency, B12 deficiency and Southeast Asian ovalocytosis among the anaemic was 41.9% (95%CI 26.4–59.2), 23.8% (95%CI 10.6–45.1) and 0.9% (95%CI 0.3–2.3%), respectively. Folate deficiency was not observed. Conclusion Even though iron deficiency remains the primary cause, minor hemoglobinopathies, B 12 deficiency and other aetiologies substantially contribute to anaemia in pregnancy in this study population. Public health interventions, including screening for minor hemoglobinopathies and multiple micronutrient supplementation in pregnancy, should be considered in the national programme for areas where these problems have been identified.

scholarly journals The impact of Helicobacter pylori infection on iron deficiency anemia in pregnancy

2017 ◽  
Vol 6 (2) ◽  
pp. 60 ◽  
Author(s):  
EamanMarouf Muhammad ◽  
MiamiAbdul Hassan Ali ◽  
BanHadi Hameed ◽  
HalaHashim Hasoobe
Keyword(s):  
Helicobacter Pylori ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Helicobacter Pylori Infection ◽  
Deficiency Anemia ◽  
Anemia In Pregnancy ◽  
The Impact ◽  
In Pregnancy

scholarly journals Safety and Efficacy of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anaemia in Pregnancy - An Intervention Study Done in a Tertiary Care Hospital of Pune

2021 ◽  
Vol 8 (22) ◽  
pp. 1803-1807
Author(s):  
Anish Kumar Vishal ◽  
Dinesh Bhasin ◽  
Vidhu Dhar Dangwal ◽  
Anurakshat Bhasin
Keyword(s):  
Iron Deficiency ◽  
Blood Transfusion ◽  
Serum Ferritin ◽  
Iron Deficiency Anaemia ◽  
Tertiary Care ◽  
Ferric Carboxymaltose ◽  
Third Trimester ◽  
Deficiency Anaemia ◽  
Anaemia In Pregnancy ◽  
In Pregnancy

BACKGROUND Anaemia is one of the major public health problems in developing nations. Iron deficiency anaemia (IDA) is the commonest type of anaemia in pregnancy. Parenteral iron therapy is a recommended modality of treatment of IDA. Inj. Ferric Carboxymaltose (FCM) is a dextran free preparation which is safe, easy to deliver and better tolerated. A maximum of 1000 mg can be infused at a time. The present study was intended to assess the efficacy and safety of Inj. FCM in the treatment of iron deficiency anaemia in the second and third trimester. METHODS This prospective study was conducted at a tertiary care centre at Pune. Pregnant women with iron deficiency anaemia of moderate and severe grade were infused 1000 mg of Inj. FCM by longer infusion protocol. A total of 165 pregnant women were included in the study. The efficacy of Inj. FCM was monitored by the rise in the haemoglobin level at 03-, 06- and 08-weeks post infusion of FCM injection and serum Ferritin levels. The safety was assessed by analysing the adverse reactions. RESULTS No serious adverse reaction was recorded in any of the patients. The rise in haemoglobin (Hb) in second and third trimester of moderate and severe grade of anaemia was significant (P < 0.001). The target level of 10 g / dl was achieved in every patient. Only 03 patients received blood transfusion and that was for obstetric indications. No blood transfusion was because of anaemia per se. The rise in serum ferritin level was also statistically significant (P < 0.001). CONCLUSIONS Inj. FCM is an excellent modality to treat iron deficiency anaemia in pregnancy. It is safe and the rise of haemoglobin with correction of anaemia is satisfactory in a short span of time. In our country where only a handful of patients had regular antenatal check-up and non-compliancy and refractory anaemia is rampant, Inj. FCM is a big boon. KEYWORDS Iron Deficiency Anaemia, Inj. Ferric Carboxymaltose, Serum Ferritin, Blood Transfusion

scholarly journals Incidence and prevalence of iron deficiency anaemia

2018 ◽  
pp. 78-81
Author(s):  
V. E. Zhorova ◽  
E. G. Khilkevich
Keyword(s):  
Adverse Effect ◽  
Iron Deficiency ◽  
General Condition ◽  
Iron Deficiency Anaemia ◽  
Ferric Iron ◽  
Clinical Manifestations ◽  
Iron Supplements ◽  
Deficiency Anaemia ◽  
Neonatal Complications ◽  
In Pregnancy

Iron deficiency anaemia (IDA) is one of the most common complications in pregnancy. It is known that IDA has an adverse effect on the condition of the mother, fetus and new-borns. The article presents modern views of the aetiology, pathogenesis, prevalence of iron deficiency anaemia, describes the clinical manifestations of this condition. The rational of treatment of IDA with modern ferric iron supplements is substantiated. It is shown that IDA therapy in pregnant and puerperal women with Maltofer is highly effective, leads to normalization of hemogram parameters, improvement of general condition, and reduction of obstetric and neonatal complications.

Sign in / Sign up

Export Citation Format

Share Document